Copyright Reports & Markets. All rights reserved.

Global Neuromyelitis Optica Drug Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Neuromyelitis Optica Drug Market Overview

      • 1.1 Product Overview and Scope of Neuromyelitis Optica Drug
      • 1.2 Neuromyelitis Optica Drug Segment by Type
        • 1.2.1 Global Neuromyelitis Optica Drug Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Glucocorticoids
        • 1.2.3 Immunoglobulin
      • 1.3 Neuromyelitis Optica Drug Segment by Application
        • 1.3.1 Neuromyelitis Optica Drug Consumption Comparison by Application (2014-2025)
        • 1.3.2 Acute attack
        • 1.3.3 Remission prophylactic treatment
      • 1.3 Global Neuromyelitis Optica Drug Market by Region
        • 1.3.1 Global Neuromyelitis Optica Drug Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Neuromyelitis Optica Drug Market Size
        • 1.4.1 Global Neuromyelitis Optica Drug Revenue (2014-2025)
        • 1.4.2 Global Neuromyelitis Optica Drug Production (2014-2025)

      2 Global Neuromyelitis Optica Drug Market Competition by Manufacturers

      • 2.1 Global Neuromyelitis Optica Drug Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Neuromyelitis Optica Drug Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Neuromyelitis Optica Drug Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Neuromyelitis Optica Drug Production Sites, Area Served, Product Types
      • 2.5 Neuromyelitis Optica Drug Market Competitive Situation and Trends
        • 2.5.1 Neuromyelitis Optica Drug Market Concentration Rate
        • 2.5.2 Neuromyelitis Optica Drug Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Neuromyelitis Optica Drug Production Market Share by Regions

      • 3.1 Global Neuromyelitis Optica Drug Production Market Share by Regions
      • 3.2 Global Neuromyelitis Optica Drug Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Neuromyelitis Optica Drug Production
        • 3.4.1 North America Neuromyelitis Optica Drug Production Growth Rate (2014-2019)
        • 3.4.2 North America Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Neuromyelitis Optica Drug Production
        • 3.5.1 Europe Neuromyelitis Optica Drug Production Growth Rate (2014-2019)
        • 3.5.2 Europe Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Neuromyelitis Optica Drug Production (2014-2019)
        • 3.6.1 China Neuromyelitis Optica Drug Production Growth Rate (2014-2019)
        • 3.6.2 China Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Neuromyelitis Optica Drug Production (2014-2019)
        • 3.7.1 Japan Neuromyelitis Optica Drug Production Growth Rate (2014-2019)
        • 3.7.2 Japan Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Neuromyelitis Optica Drug Consumption by Regions

      • 4.1 Global Neuromyelitis Optica Drug Consumption by Regions
      • 4.2 North America Neuromyelitis Optica Drug Consumption (2014-2019)
      • 4.3 Europe Neuromyelitis Optica Drug Consumption (2014-2019)
      • 4.4 China Neuromyelitis Optica Drug Consumption (2014-2019)
      • 4.5 Japan Neuromyelitis Optica Drug Consumption (2014-2019)

      5 Global Neuromyelitis Optica Drug Production, Revenue, Price Trend by Type

      • 5.1 Global Neuromyelitis Optica Drug Production Market Share by Type (2014-2019)
      • 5.2 Global Neuromyelitis Optica Drug Revenue Market Share by Type (2014-2019)
      • 5.3 Global Neuromyelitis Optica Drug Price by Type (2014-2019)
      • 5.4 Global Neuromyelitis Optica Drug Production Growth by Type (2014-2019)

      6 Global Neuromyelitis Optica Drug Market Analysis by Applications

      • 6.1 Global Neuromyelitis Optica Drug Consumption Market Share by Application (2014-2019)
      • 6.2 Global Neuromyelitis Optica Drug Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Neuromyelitis Optica Drug Business

      • 7.1 Pfizer
        • 7.1.1 Pfizer Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.1.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.1.3 Pfizer Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 FRESENIUS
        • 7.2.1 FRESENIUS Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.2.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.2.3 FRESENIUS Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 TEVA
        • 7.3.1 TEVA Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.3.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.3.3 TEVA Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 SANDOZ
        • 7.4.1 SANDOZ Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.4.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.4.3 SANDOZ Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Intas
        • 7.5.1 Intas Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.5.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.5.3 Intas Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Gyjtrs
        • 7.6.1 Gyjtrs Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.6.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.6.3 Gyjtrs Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 NANG KUANG
        • 7.7.1 NANG KUANG Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.7.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.7.3 NANG KUANG Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Tianjin Kingyork
        • 7.8.1 Tianjin Kingyork Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.8.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Baxter
        • 7.9.1 Baxter Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.9.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.9.3 Baxter Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 CSL
        • 7.10.1 CSL Neuromyelitis Optica Drug Production Sites and Area Served
        • 7.10.2 Neuromyelitis Optica Drug Product Introduction, Application and Specification
        • 7.10.3 CSL Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Grifols
      • 7.12 Octapharma
      • 7.13 CBOP

      8 Neuromyelitis Optica Drug Manufacturing Cost Analysis

      • 8.1 Neuromyelitis Optica Drug Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Neuromyelitis Optica Drug
      • 8.4 Neuromyelitis Optica Drug Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Neuromyelitis Optica Drug Distributors List
      • 9.3 Neuromyelitis Optica Drug Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Neuromyelitis Optica Drug Market Forecast

      • 11.1 Global Neuromyelitis Optica Drug Production, Revenue Forecast
        • 11.1.1 Global Neuromyelitis Optica Drug Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Neuromyelitis Optica Drug Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Neuromyelitis Optica Drug Price and Trend Forecast (2019-2025)
      • 11.2 Global Neuromyelitis Optica Drug Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Neuromyelitis Optica Drug Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Neuromyelitis Optica Drug Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Neuromyelitis Optica Drug Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Neuromyelitis Optica Drug Production, Revenue Forecast (2019-2025)
      • 11.3 Global Neuromyelitis Optica Drug Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Neuromyelitis Optica Drug Consumption Forecast (2019-2025)
        • 11.3.2 Europe Neuromyelitis Optica Drug Consumption Forecast (2019-2025)
        • 11.3.3 China Neuromyelitis Optica Drug Consumption Forecast (2019-2025)
        • 11.3.4 Japan Neuromyelitis Optica Drug Consumption Forecast (2019-2025)
      • 11.4 Global Neuromyelitis Optica Drug Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Neuromyelitis Optica Drug Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
        Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

        In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
        North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.
        Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.

        The global Neuromyelitis Optica Drug market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Neuromyelitis Optica Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neuromyelitis Optica Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Pfizer
        FRESENIUS
        TEVA
        SANDOZ
        Intas
        Gyjtrs
        NANG KUANG
        Tianjin Kingyork
        Baxter
        CSL
        Grifols
        Octapharma
        CBOP

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Glucocorticoids
        Immunoglobulin

        Segment by Application
        Acute attack
        Remission prophylactic treatment

        Buy now